CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- PositionCurrent ratio is 18.54×, higher than 95% of its Medical Devices peers (median 3.87×)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
4.90%
Annual Rate
KRW 228.00Paid annual
Payout Ratio
17.2%Sustainable
Payback Period
20.6 yr
Last Ex-Dividend
Mar 30, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
469.24BKRW338.48M · vs all stocks (USD)
Revenue (TTM)
126.41BKRW91.18M · vs all stocks (USD)
Profit Margin
-99.43%vs Medical Devices peers
Beta
0.6310xvs all stocks
52-Week Change
-23.52%vs all stocks
Market Capitalization
469.24BKRW338.48M · vs all stocks (USD)
Enterprise Value
104.69BKRW75.51M · vs all stocks (USD)
Price to Sales (TTM)
3.72xvs Medical Devices peers
Price to Book (MRQ)
0.3016xvs Medical Devices peers
Enterprise to Revenue
0.8280xvs Medical Devices peers
Enterprise to EBITDA
3.43xvs Medical Devices peers
Gross Margin
53.70%vs Medical Devices peers
Profit Margin
-99.43%vs Medical Devices peers
Operating Margin
23.27%vs Medical Devices peers
Return on Assets (TTM)
0.77%vs Medical Devices peers
Return on Equity (TTM)
-7.79%vs Medical Devices peers
Revenue (TTM)
126.41BKRW91.18M · vs all stocks (USD)
Revenue per Share (TTM)
1.25KKRWUpdated Sep 21, 2026Quarterly Revenue Growth
12.20%vs Medical Devices peers
Gross Profit (TTM)
71.39BKRW51.50M · vs all stocks (USD)
EBITDA (TTM)
30.52BKRW22.02M · vs all stocks (USD)
Net Income (TTM)
-125.69BKRW-90.66M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-89.30%vs Medical Devices peers
Operating Cash Flow (TTM)
45.56BKRW32.86M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
23.76BKRW17.14M · vs all stocks (USD)
Trailing Annual Dividend Rate
228.00KRWUpdated Sep 21, 2026Trailing Annual Dividend Yield
4.90%vs all stocks
Payout Ratio
17.23%vs Medical Devices peers
Revenue
118.32BKRWFY2025 · Dec 31, 2025Cost of Goods Sold
52.56BKRWFY2025 · Dec 31, 2025Gross Profit
65.77BKRWFY2025 · Dec 31, 2025Operating Income
16.81BKRW12.12M · vs all stocks (USD)
Pre-tax Income
-87.57BKRWFY2025 · Dec 31, 2025Income Tax Expense
-70.26MKRWFY2025 · Dec 31, 2025Net Income
-87.50BKRWFY2025 · Dec 31, 2025EBIT
-87.28BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
-78.25BKRWFY2025 · Dec 31, 2025Research & Development
16.84BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
11.79BKRWFY2025 · Dec 31, 2025Other Operating Expenses
1.17BKRWFY2025 · Dec 31, 2025Non-operating Interest Income
14.70BKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
287.12MKRWFY2025 · Dec 31, 2025EPS (Basic)
-865.00KRWFY2025 · Dec 31, 2025EPS (Diluted)
-865.00KRWFY2025 · Dec 31, 2025Basic Shares Outstanding
101.15MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
101.15MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-87.50BKRWFY2025 · Dec 31, 2025Operating Cash Flow
-104.72BKRWFY2025 · Dec 31, 2025Free Cash Flow
-105.15BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
17.87BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-87.50BKRWFY2025 · Dec 31, 2025Stock-based Compensation
264.80MKRWFY2025 · Dec 31, 2025Other Non-cash Items
-14.42BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-10.67BKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
7.61BKRWFY2025 · Dec 31, 2025Capital Expenditures
-436.49MKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-158.52MKRWFY2025 · Dec 31, 2025Net Acquisitions
-52.38BKRWFY2025 · Dec 31, 2025Purchase of Investments
-449.41BKRWFY2025 · Dec 31, 2025Sale of Investments
424.37BKRWFY2025 · Dec 31, 2025Other Investing Activity
550.00KRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-77.85BKRWFY2025 · Dec 31, 2025Common Stock Repurchase
-5.00BKRWFY2025 · Dec 31, 2025Common Dividends Paid
-20.27BKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
-25.27BKRWFY2025 · Dec 31, 2025Shares Outstanding
100.75MSharesUpdated Sep 21, 2026Float Shares
13.19MSharesUpdated Sep 21, 2026% Held by Insiders
80.23%vs all stocks
% Held by Institutions
5.97%vs all stocks
Total Cash (MRQ)
368.27BKRW265.64M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.65KKRWUpdated Sep 21, 2026Total Debt (MRQ)
3.21BKRW2.32M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0021xvs Medical Devices peers
Current Ratio (MRQ)
18.54xvs Medical Devices peers
Book Value per Share (MRQ)
15.42KKRWUpdated Sep 21, 2026Total Assets
1.56TKRW1.12B · vs all stocks (USD)
Total Current Assets
406.82BKRWFY2025 · Dec 31, 2025Total Liabilities
44.65BKRWFY2025 · Dec 31, 2025Total Non-current Assets
1.15TKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
31.53BKRWFY2025 · Dec 31, 2025Total Current Liabilities
13.12BKRWFY2025 · Dec 31, 2025Cash Equivalents
17.87BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
17.87BKRWFY2025 · Dec 31, 2025Other Short-term Investments
321.94BKRWFY2025 · Dec 31, 2025Accounts Receivable
31.46BKRWFY2025 · Dec 31, 2025Inventory
27.69BKRWFY2025 · Dec 31, 2025Accounts Payable
4.16BKRWFY2025 · Dec 31, 2025Short-term Debt
1.49BKRWFY2025 · Dec 31, 2025Other Current Liabilities
87.72MKRWFY2025 · Dec 31, 2025Long-term Debt
2.16BKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
330.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
51.03BKRWFY2025 · Dec 31, 2025Retained Earnings
1.34TKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
1.51TKRW1.09B · vs all stocks (USD)
Treasury Stock
8.11BKRWFY2025 · Dec 31, 202552-Week Low
4.05KKRWUpdated Sep 21, 202652-Week High
6.30KKRWUpdated Sep 21, 202652-Week Change
-23.52%vs all stocks
Beta
0.6310xvs all stocks
50-Day MA
4.71KKRWUpdated Sep 21, 2026200-Day MA
5.11KKRWUpdated Sep 21, 2026Avg 10-Day Volume
38.94KSharesUpdated Sep 21, 2026Avg 30-Day Volume
56.29KSharesUpdated Sep 21, 2026Diluted EPS (TTM)
-865.00KRWUpdated Sep 21, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
How is this stock valued?
Inverted P/B With Liquidity And Equity Ratio
It trades below book value, with current assets ample and the balance sheet equity-funded.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 18.54×, higher than 95% of its Medical Devices peers (median 3.87×)Significant
Current ratio: 18.54Industry median: 3.87Industry P95: 12.55Peers compared: 102
Debt-to-equity is 0×, lower than 95% of its Medical Devices peers (median 0.11×)Notable
Debt-to-equity: 0.00Industry median: 0.11Industry P5: 0.00Peers compared: 102
Price-to-book is 0.3×, lower than 95% of its Medical Devices peers (median 2.51×)Notable
Price-to-book: 0.30Industry median: 2.51Industry P5: 0.60Peers compared: 102
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.54Profit Margin: -0.99
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Suzhou Fushilai Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Benitec Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Shapuaisi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jilin Jian Yisheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Shanxi C&Y Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Zhenyuan Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Zhejiang Xinguang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ocugen Inc.
Tier 1ProductionApproval-Gated PipelineRule
Enanta Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Surrozen, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Fulgent Genetics Inc.
2 interpretationsLow-Leverage Liquidity ConfigurationInverted P/B With Liquidity And Equity Ratio
Saratoga Investama Sedaya Tbk
2 interpretationsLow-Leverage Liquidity ConfigurationInverted P/B With Liquidity And Equity Ratio
StealthGas Inc.
2 interpretationsLow-Leverage Liquidity ConfigurationInverted P/B With Liquidity And Equity Ratio